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The Journal of Immunology
Membrane Type 1 Matrix Metalloproteinase Regulates
Monocyte Migration and Collagen Destruction in Tuberculosis
Tarangini Sathyamoorthy,* Liku B. Tezera,† Naomi F. Walker,*,‡ Sara Brilha,*
Luisa Saraiva,* Francesco A. Mauri,x Robert J. Wilkinson,‡,{,‖ Jon S. Friedland,* and
Paul T. Elkington*,†,#
Tuberculosis (TB) remains a global pandemic and drug resistance is rising. Multicellular granuloma formation is the pathological
hallmark of Mycobacterium tuberculosis infection. The membrane type 1 matrix metalloproteinase (MT1-MMP or MMP-14) is
a collagenase that is key in leukocyte migration and collagen destruction. In patients with TB, induced sputum MT1-MMP mRNA
levels were increased 5.1-fold compared with matched controls and correlated positively with extent of lung infiltration on chest
radiographs (r = 0.483; p < 0.05). M. tuberculosis infection of primary human monocytes increased MT1-MMP surface expression
31.7-fold and gene expression 24.5-fold. M. tuberculosis–infected monocytes degraded collagen matrix in an MT1-MMP–dependent
manner, and MT1-MMP neutralization decreased collagen degradation by 73%. In human TB granulomas, MT1-MMP immu-
noreactivity was observed in macrophages throughout the granuloma. Monocyte–monocyte networks caused a 17.5-fold increase
in MT1-MMP surface expression dependent on p38 MAPK and G protein–coupled receptor-dependent signaling. Monocytes
migrating toward agarose beads impregnated with conditioned media from M. tuberculosis–infected monocytes expressed
MT1-MMP. Neutralization of MT1-MMP activity decreased this M. tuberculosis network–dependent monocyte migration by
44%. Taken together, we demonstrate that MT1-MMP is central to two key elements of TB pathogenesis, causing collagen
degradation and regulating monocyte migration. The Journal of Immunology, 2015, 195: 000–000.
N
ew therapeutic approaches are needed to achieve tu-
berculosis (TB) control, a disease that caused 9.0 million
cases and 1.5 million deaths in 2013 (1). Pathology
results from the interaction between Mycobacterium tuberculosis
and the host immune response (2). This pathology is particularly
critical in cavitatory pulmonary TB, which results in transmission
of infection (3, 4), increased drug resistance (5, 6), morbidity, and
mortality (7–9). Improved understanding of host factors that drive
lung pathology is required to design novel therapeutic and vac-
cination strategies (2).
Breakdown of the pulmonary extracellular matrix (ECM) in TB
follows inflammatory cellular infiltration and granuloma formation
in lung tissue. Secreted matrix metalloproteinases (MMPs) are
emerging as key mediators in driving TB pathology. MMPs are
zinc-dependent proteolytic enzymes that regulate cellular migra-
tion and have the potential to degrade all ECM fibrils (10). MMP-1
causes collagen destruction, whereas the gelatinase MMP-9 plays
a critical role in regulating a chemotactic gradient for monocytes
toward TB granulomas (11). Membrane-bound MMPs are im-
portant in cell migration in diverse inflammatory conditions and
can also act as collagenases (12), but their role in TB is poorly
understood.
Membrane type 1 MMP (MT1-MMP) was the first membrane-
bound MMP to be discovered (13). MT1-MMP degrades col-
lagen in the immediate pericellular environment and is key in
cell migration through ECM (14–16). MT1-MMP gene expres-
sion has been found to be upregulated in M. tuberculosis–infected
monocytes (17) and by unbiased analyses of gene expression in TB
(18, 19). However, the functional role of MT1-MMP in TB path-
ogenesis has not been explored. We hypothesized that MT1-MMP
may drive inflammatory cell influx to foci of M. tuberculosis in-
fection and also contribute to collagen degradation. We dem-
onstrate that MT1-MMP expression is increased in patients
with pulmonary TB and is upregulated in primary human mono-
cytes by M. tuberculosis infection. MT1-MMP is expressed
throughout TB granulomas and is also upregulated by monocyte–
monocyte networks. MT1-MMP has dual effects in TB, both
causing collagen destruction and also regulating cellular mi-
gration, implying a potentially central role in disease patho-
genesis.
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Materials and Methods
Sputum collection and processing
The clinical study was approved by the University of Cape Town Research
Ethics Committee (reference no. 516/2011). Written informed consent was
obtained in all cases. Participants were prospectively recruited from the
Ubuntu clinic in the township of Khayelitsha, Cape Town, South Africa. TB
patients met at least one inclusion criteria from sputum smear positive for
acid-fast bacillus on microscopy or sputum Gene Xpert positive or sputum
culture positive for M. tuberculosis or clinical features highly suggestive of
TB with diagnostic features on chest radiograph and started on TB treatment
by a clinician, conforming to the World Health Organization clinical case
definition. Control patients were individuals who were sputum smear and
culture negative forM. tuberculosis with absent clinical and chest radiograph
features of TB. Only HIV negative patients recruited within 72 h of com-
mencing TB treatment were included. Sputum induction, transportation, and
mucolysis were performed as described (20). The mucoid layer was filtered
by passing through 100-mm pore size strainer (BD Biosciences) and then
centrifuged at 500 3 g for 10 min. The cell pellet was aspirated and 1.5 ml
cold TRI reagent (Sigma-Aldrich) added before vortexing. Samples were
stored at 280˚C before proceeding to RT-PCR analysis. The extent of in-
filtration on chest radiograph was scored on a scale of 0–10, according to the
number of segments involved, using an established scoring system (20).
Real-time PCR
Sputum was lysed in TRI reagent (Sigma-Aldrich). Total RNA was extracted
using phenol/chloroform extraction and the PureLink RNAmini kit (Invitrogen)
according to manufacturer’s instructions. RNA was reverse transcribed using
the QuantiTect reverse transcription kit (Qiagen) according to the manu-
facturer’s instructions. RT-PCR was performed on a Stratagene Mx3000Pro
machine using the synthesized cDNA, Brilliant II Taq polymerase (Agilent
Technologies), and primers/probes (Applied Biosystems) for MT1-MMP and
the reference genes b-actin and 18S. The cycle thresholds (Ct) for MT1-MMP
and b-actin were used to indicate the relative amount of mRNA in each sample.
Monocyte purification and stimulation
Monocytes were isolated from single donor leukocyte cones (National Health
Service Blood and Transfusion, London, U.K.) or fresh blood from healthy
donors by density gradient centrifugation over Ficoll-Paque (GE Healthcare
Life Sciences) and adhesion purification. Monocyte purity was.95% by flow
cytometry and viability was .95% by trypan blue exclusion assay. Mono-
cytes were plated in tissue culture plates or chamber slides. Experiments
were commenced immediately using RPMI 1640 supplemented with 2 mM
glutamine, 10 mg/ml ampicillin, with 10% heat-inactivated FCS (Biowest) in
a humidified incubator supplemented with 5% CO2 at 37˚C. Stimuli used
were direct infection with M. tuberculosis strain H37Rv or conditioned
medium from M. tuberculosis–infected monocytes (CoMTb).
M. tuberculosis culture
M. tuberculosis H37Rv was cultured in Middlebrook 7H9 medium (BD Bio-
sciences, Oxford, U.K.). M. tuberculosis in mid-log growth at an OD of 0.60
(Biowave cell density meter, WPA) was used for infecting monocytes imme-
diately after adhesion purification at a multiplicity of infection (MOI) of 1.
Preparation of CoMTb
Monocytes were plated in RPMI 1640 supplemented with 2 mM glutamine
and 10 mg/ml ampicillin and immediately infected with M. tuberculosis at
an MOI of 1. After 24 h, the cell culture medium was aspirated and filtered
through a 0.2-mm Anopore membrane (Whatman) to remove live M. tu-
berculosis and MMPs (21). The resulting cell culture supernatant is termed
CoMTb and contains an M. tuberculosis–induced intercellular network of
cytokines, chemokines, and growth factors. This was used to stimulate
monocytes at a 1:5 dilution immediately after adhesion purification.
Conditioned medium from control monocytes is the cell culture superna-
tant from uninfected monocytes after 24 h of incubation.
Flow cytometry
Adhesion-purified monocytes were harvested from tissue culture plates
using cell dissociation buffer (enzyme-free) (Invitrogen) at 37˚C for 15 min
and a cell scraper. Cells were centrifuged at 1200 rpm for 5 min for pel-
leting and blocked with 10% heat-inactivated human serum/1% BSA, then
stained with a PE-conjugated mouse anti–MT1-MMP Ab (R&D Systems,
FAB9181P). When cells had been infected with M. tuberculosis, they were
then fixed in 2% paraformaldehyde. Flow cytometry was performed im-
mediately after staining on a FACSCalibur (BD Biosciences). Live cells
were gated, confirmed by propidium iodide staining. Harvested monocytes
were identified for gating on the forward scatter/side scatter plot. Negative
controls were unstained, unstimulated monocytes. FlowJo software (ver-
sion 7.6.2) was used for data analysis.
Western blotting
Monocytes were harvested into SDS lysis buffer (62.5 mM Tris, 2% SDS,
10% glycerol, 50 mM DDT, 0.01% bromphenol blue; Sigma-Aldrich),
denatured at 90˚C, loaded on a NuPAGE 4–12% Bis-Tris gel (Invitrogen),
and separated by electrophoresis at 200 V for 50 min in MOPS running
buffer (Invitrogen). Proteins were electrotransferred to a nitrocellulose
membrane (GE Healthcare Life Sciences) at 30 V for 90 min, blocked with
0.1% Tween 20 (Sigma-Aldrich)/5% nonfat milk for 1 h, and then incu-
bated with primary Ab overnight. Detection was by HRP-conjugated
secondary Ab and chemiluminescent substrate (ECL Plus Western blotting
detection system, GE Healthcare Life Sciences). Densitometry was ana-
lyzed using Image J software version 1.44p (National Institutes of Health,
Bethesda, MD). For MT1-MMP Western blots, the primary Abs were
rabbit anti–MT1-MMP (Millipore, AB 6004) and mouse anti–b-actin
(Sigma-Aldrich, A1978). The secondary Abs were HRP-conjugated goat
anti-rabbit (Cell Signaling Technology) and goat anti-mouse (Jackson
ImmunoResearch Laboratories). For phosphorylated Western blots, the
primary Abs were to phosphorylated and total p38/ERK MAPK (Cell
Signaling Technology). The secondary Ab was HRP-conjugated goat
anti-rabbit (Cell Signaling Technology).
Immunofluorescent microscopy and fluorescent collagen
degradation assay
Monocytes in chamber slides (PAA Laboratories) were blocked with 5%
human serum/1% BSA for 1 h and stained with mouse anti MT1-MMP
(Millipore, MAB3328), goat anti-mouse Alexa Fluor 647–conjugated sec-
ondary Ab (Invitrogen, A-21235), and DAPI nuclear stain (Invitrogen).
Permeabalization was performed with 0.5% Triton X-100 (Merck) and fix-
ation with 2% paraformaldehyde. For the fluorescent collagen degradation
assay, chamber slides were coated with FITC-conjugated type I collagen
from bovine skin (Sigma-Aldrich), prior to adhering the monocytes using
a modification of a previously described technique. Poly-L-lysine (0.005%)
(Sigma-Aldrich) was first used to create a substratum to improve cell ad-
herence, then 0.5% glutaraldehyde (BDH) to covalently couple the sub-
stratum to the fluorescent collagen. This created a thin two-dimensional
collagen matrix for detection of pericellular collagen degradation by loss
of fluorescent signal. Fluorescent microscopy was performed on a Leica TCS
SP5 confocal microscope with the Leica application suite 2.6.2 software.
Images were processed and quantified using ImageJ software version 1.44p
(National Institutes of Health).
MMP-1 and TIMP quantitation
MMP-1 concentrations in cell culture supernatants were measured by
Luminex (R&D Systems kit, Bio-Rad Luminex 200 machine). TIMP-1 and
-2 concentrations were analyzed by ELISA (R&D Systems).
Lung immunohistochemistry
Lung tissue from five patients with culture-proven M. tuberculosis was
studied. Control tissue was obtained from uninvolved lung parenchyma of
patients who underwent a surgical procedure for lung cancer. MT1-MMP
immunoreactivity was evaluated using the mouse mAb 114-6G6 (Abcam,
ab77965). Briefly, sections were rehydrated in graded alcohols and heated
in a microwave oven at 900 W for 20 min in citrate buffer at pH 6. They
were cooled at room temperature before immunostaining. MT1-MMP
mAb was used at a concentration of 20 mg/ml for 2 h at room tempera-
ture and then processed with a polymer-HRP kit (BioGenex, San Ramon,
CA) with diaminobenzidine development and Mayer hematoxylin coun-
terstaining. Breast and colon tissues were used as a positive external
control. Negative controls were obtained by omitting the primary Ab and
using competing peptide used to raise the primary Ab. Slides were
reviewed with a histopathologist, and images were taken using an
Olympus BX51 microscope. This project was approved by the Ham-
mersmith and Queen Charlotte’s Research Ethics Committee (reference
no. 07/H0707/120).
Chemical inhibitors and MT1-MMP inhibitory Ab
For chemical inhibition experiments, monocytes were preincubated with the
specified inhibitors for 1 h prior to CoMTb stimulation. The p38 MAPK
inhibitor SB203580 (Enzo Life Sciences) and ERK MAPK inhibitor
PD98059 (Calbiochem) were used. The GPCR inhibitor pertussis toxin
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(Calbiochem) was used to block chemokine signaling. A mouse anti MT1-
MMP Ab (MAB3328, Millipore) was used to inhibit MT1-MMP activity.
Agarose bead assay
An agarose bead assay was used to investigate monocyte migration toward
CoMTb using a modification of a previous assay (22). RPMI 1640 or CoMTb
was added to a 0.5% agarose solution at 40˚C at a 1:10 dilution. Beads (10 ml)
were pipetted on to cover glass-bottom chamber slides (PAA Laboratories)
precoated with type I collagen as described above. The slide was left at 4˚C for
5 min for the agarose to set before adhering monocytes to the slide. Manganese
(0.25 mM) was added to the media to activate integrins on the monocytes,
which are required for monocyte adhesion to extracellular matrix during mi-
gration (23, 24). Images were captured using an Olympus E-620 camera at-
tached to the Olympus CK2 light microscope. Images were processed and
quantified using ImageJ software version 1.44p (National Institutes of Health).
Migration was quantified by measuring four radial points per sphere and
measuring the diameter of monocyte clusters, and two spheres per condition
were analyzed.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 by a Student
t test, Mann–Whitney U test, or one-way ANOVA with a Tukey post hoc
analysis as appropriate. A p value , 0.05 was taken as significant.
Results
MT1-MMP expression is increased in sputum of patients with
TB and correlates with lung infiltration
We investigatedMT1-MMP gene expression in induced sputum from
patients with pulmonary TB (n = 15) and controls (n = 10). Clinical
features of patient cohort are in Table I. The TB and control group
were closely matched for age, but there was a higher proportion of
females in the control group, which may reflect differences in health-
seeking behavior (25). TB patients had significantly more symptoms
(fever, cough, night sweats, weight loss, and breathlessness), a lower
body mass index, and a higher number of abnormal respiratory
examinations, consistent with the diagnosis of pulmonary TB. All
control patients were smear and culture negative for M. tuberculosis.
Twelve of the TB cases were culture positive and of the three
remaining cases, one was smear positive. These three patients all had
clinical and radiological features highly suggestive of TB and were
started on TB therapy by their treating clinician. MT1-MMP gene
expression normalized to b-actin was 5.1-fold higher in the sputum
of patients with TB compared with controls (Fig. 1A, p , 0.05).
MT1-MMP gene expression positively correlated with the extent of
lung infiltration on chest radiograph (Fig. 1B; r = 0.483, p , 0.05).
M. tuberculosis infection of primary human monocytes drives
MT1-MMP gene and protein expression
In a primary human cellular model, M. tuberculosis infection in-
creased monocyte MT1-MMP surface expression analyzed by flow
cytometry compared with uninfected cells at 24 h (Fig. 2A).
Quantification showed a 31.7-fold increase in MT1-MMP surface
expression after M. tuberculosis infection (Fig. 2B, p , 0.05).
Table I. Characteristics of patient cohort
Patient Characteristics Control TB
Total no. 10 15
Male/female 4/6 10/5
Median age (range), years 31.5 (21–48) 40 (24–73) NS
Symptoms (duration), days
Any 1 15
Fever 1 11
Cough 0 14
Hemoptysis 0 1
Night sweats 1 12
Weight loss 0 8
Breathlessness 0 6
Pleuritic pain 1 11
Anorexia 1 3
Median duration (range) 0 (0–4) 30 (7–98) p , 0.0001
Examination
Median body mass index (range) 25.4 (17.5– 55.7) 21.6 (18.5– 29.1) p , 0.05
Temperature . 37.5˚C 0 1 NS
Abnormal respiratory examination 4 13
Smear
Positive 0 8
Negative 10 7
Culture
Positive 0 12
Negative 10 3a
Significant differences are indicated in the right-hand column. All patients had clinical features highly suggestive of TB with diagnostic
features on chest radiograph and were commenced on antituberculous therapy by the treating physician.
aOne of these three patients was smear positive.
FIGURE 1. MT1-MMP gene expression is increased in the sputum of
patients with TB and correlates with lung infiltration on chest radiographs. In-
duced sputum samples were collected prospectively from healthy controls (n =
10) and TB patients (n = 15) in Cape Town, South Africa. RNAwas extracted
from the sputum cell pellets, and MT1-MMP and b-actin gene expression were
analyzed by RT-PCR. (A) MT1-MMP gene expression (normalized to b-actin)
was increased in the sputum of TB patients compared with healthy controls.
Horizontal line indicates median value. *p, 0.05 byMann–WhitneyU test. (B)
The extent of lung infiltration on chest radiograph was scored on a scale of 0–
10. Sputum MT1-MMP relative expression positively correlated with lung in-
filtration by Spearman correlation coefficient (r = 0.483, *p , 0.05).
The Journal of Immunology 3
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Next, we analyzed the kinetics of MT1-MMP gene expression
in M. tuberculosis–infected monocytes. M. tuberculosis infection
caused a nonsignificant 1.4-fold increase in MT1-MMP gene ex-
pression normalized to b-actin at 3 h, rising to 10.6-fold at 6 h and
73.4-fold at 24 h relative to uninfected monocytes (Fig. 2C). In-
creased MT1-MMP mRNA accumulation was associated with
increased MT1-MMP total protein in M. tuberculosis–infected
monocytes analyzed by Western blotting (Fig. 2D). M. tuberculosis
infection of monocytes caused a 14.8-fold increase in MT1-MMP
protein in whole-cell lysates compared with uninfected monocytes
at 48 h (Fig. 2D, p , 0.01). M. tuberculosis also increased secretion
of MMP-1 into cell culture supernatants analyzed by Luminex array
(Supplemental Fig. 1), although this concentration was below the
sensitivity of detection by casein zymography (data not shown).
M. tuberculosis–dependent MT1-MMP expression causes
collagen degradation
To investigate whether MT1-MMP caused matrix breakdown, we
analyzed degradation of fluorescent collagen. M. tuberculosis in-
fection increased MT1-MMP surface expression on unpermea-
FIGURE 2. M. tuberculosis infection drives monocyte MT1-MMP expression and collagen degradation. (A) Human monocytes were infected with M.
tuberculosis (MOI of 1) and MT1-MMP expression was analyzed by flow cytometry at 24 h. Increased MT1-MMP surface expression is demonstrated by
greater mean fluorescence intensity (MFI). (B) MFI analysis confirms increased MT1-MMP expression. (C) M. tuberculosis infection causes a progressive
increase in MT1-MMP mRNA accumulation infected monocytes (normalized to b-actin). (D) M. tuberculosis infection increases total cellular MT1-MMP
at 48 h as analyzed by Western blotting, which was confirmed by densitometric analysis. b-actin was probed as a loading control. (E) M. tuberculosis
infection causes collagen degradation around monocytes. Human monocytes were seeded on wells coated with fluorescently conjugated type I collagen and
infected withM. tuberculosis. MT1-MMP surface expression and collagen degradation were analyzed by immunofluorescent staining and microscopy. Blue
is DAPI nuclear stain, magenta is MT1-MMP, and green is type I collagen. Increased collagen degradation occurred at 24 h in M. tuberculosis–infected
wells, and MT1-MMP surface expression colocalizes with the areas of collagen degradation. For (B)–(D), the mean 6 SD values of experiments performed
in triplicate are shown and are representative of a minimum of two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001 by Student t test.
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balized monocytes at 24 h (Fig. 2E). M. tuberculosis infection
caused collagen degradation, indicated by loss of fluorescence, and
this collagen degradation colocalized with MT1-MMP expression
(Fig. 2E, merged image). MT1-MMP neutralization inhibited such
M. tuberculosis–driven collagen degradation. Zones of collagen
breakdown are present around M. tuberculosis–infected monocytes
(Fig. 3B), and incubation with an MT1-MMP inhibitory Ab sup-
presses this collagen breakdown (Fig. 3C). A matched isotype
control Ab did not inhibit collage breakdown (Fig. 3D). Quantifi-
cation of degraded collagen demonstrated that M. tuberculosis in-
fection caused 42.8-fold greater collagen degradation by monocytes
compared with uninfected cells (Fig. 3E). MT1-MMP inhibition
resulted in a 73% reduction in this collagen breakdown (p, 0.001).
MT1-MMP is expressed in granulomas of patients with TB and
is upregulated by M. tuberculosis–induced intercellular
networks
Next, biopsies from patients with active TB and normal lung tissue
were immunostained for MT1-MMP. MT1-MMP immunoreac-
tivity was expressed in TB granulomas, including in Langerhans
multinucleate giant cells and in surrounding epithelioid macro-
phages (Fig. 4A). In lung tissue of control subjects, MT1-MMP
immunoreactivity was only detected in alveolar macrophages.
Because MT1-MMP was diffusely expressed in the granuloma,
but mycobacteria are relatively sparse within granulomas (26), we
investigated whether M. tuberculosis–induced intercellular net-
works increased MT1-MMP expression. We stimulated cells with
CoMTb to model these networks. CoMTb upregulated surface
MT1-MMP expression in unpermeabalized and permeabilized
monocytes at 24 h of incubation compared with unstimulated cells
(Fig. 4B).
M. tuberculosis–induced MT1-MMP expression is regulated by
p38 MAPK and chemokine signaling
Flow cytometry analysis demonstrated an increase in MT1-MMP
mean fluorescence intensity in CoMTb-stimulated monocytes
compared with unstimulated cells analyzed at 24 h (Fig. 5A), with
a 17.5-fold increase in MT1-MMP surface expression with CoMTb
FIGURE 3. M. tuberculosis–driven collagen degradation is MT1-MMP–dependent. (A and B) Human monocytes were seeded on FITC-conjugated type I
collagen and infected with M. tuberculosis. Collagen degradation was analyzed by immunofluorescent microscopy. Blue is DAPI nuclear stain; green is
type I collagen. M. tuberculosis infection causes greater collagen degradation. (C) MT1-MMP activity was neutralized with an inhibitory anti-MT1-MMP
Ab (MAB3328, Millipore) at 10 mg/ml. MT1-MMP inhibition inhibited areas of collagen breakdown. (D) An isotype control Ab did not inhibit collagen
degradation. (E) Fluorescence quantitation confirms collagen degradation is MT1-MMP–dependent. Data are from a single experiment and are repre-
sentative of three independent experiments. Mean values 6 SD are shown. ***p , 0.001 by one-way ANOVA with a Tukey post hoc test.
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(Fig. 5B, p, 0.05). CoMTb stimulation drove a 5.2-fold increase in
MT1-MMP gene expression at 3 h, rising to 22.6-fold at 6 h and
45.4-fold at 24 h (Fig. 5C). CoMTb may contain and drive the
production of inhibitors, so we analyzed TIMP-1 and -2 secretion
from monocytes stimulated with CoMTb at 24 h. TIMP-1 con-
centrations were upregulated by CoMTb stimulation (Fig. 5D), but
TIMP-2, the specific MT1-MMP inhibitor (27), was suppressed
(Fig. 5E). MT1-MMP expression may be regulated by the MAPK
pathways in response to other stimuli (28). CoMTb stimulation of
monocytes caused a 3-fold increase in p38 phosphorylation and
a 2.7-fold increase in ERK phosphorylation compared with unstim-
ulated cells at 30 min incubation analyzed by Western blotting
(Fig. 5F). Specific inhibition of the p38 MAPK signaling pathway
by SB203580 resulted in reduced CoMTb-driven surface MT1-
MMP expression on monocytes at 24 h (Fig. 5G, p , 0.05). In
contrast, inhibition of the ERK MAPK pathway with PD98059
(10 mM) had no effect (data not shown).
Because CC chemokines are critical in monocyte migration to
sites of infection, including TB (29), we measured chemokines in
CoMTb from four different donors by Luminex array (Supplemental
Table I). Multiple chemokine concentrations, including CCL2
(MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1b), CXCL8 (IL-8), and
CXCL9 (MIG), were increased. Therefore, we chemically inhibited
all chemokine signaling via GPCRs with pertussis toxin to inves-
tigate whether chemokines in CoMTb were driving MT1-MMP
expression. Pertussis caused a 35% reduction in CoMTb-driven
MT1-MMP expression on unpermeabilized monocytes at 24 h
(Fig. 5H, p , 0.05). Propidium iodide staining showed that per-
tussis did not increase cell death (data not shown). We stimulated
monocytes with CCL-2 (MCP-1), which has previously been
shown to upregulate MT1-MMP in endothelial cells (30), but
CCL-2 did not increase monocyte MT1-MMP surface expression
as a single stimulus.
MT1-MMP is critical to monocyte migration
Finally, we specifically investigated the role of MT1-MMP in
monocyte migration using a modified agarose drop migration assay
(22). Monocytes migrated toward CoMTb-impregnated agarose
beads, forming clusters around the edge at 24 h that were not ob-
served in control beads (Fig. 6A, 6D). The migrating monocytes
expressed increased levels of membrane-associated MT1-MMP than
cells around the control bead (Fig. 6B, 6E). To investigate the
functional relevance, we specifically inhibited MT1-MMP activity
with a neutralizing Ab. MT1-MMP inhibition reduced the size of
monocyte clusters around beads compared with untreated cells
(Fig. 7B, 7C). Isotype control Ab did not affect cell migration
(Fig. 7D). Migration was quantified using two beads per condition,
with monocyte migration measured at four radial points per sphere.
The diameter of the monocyte clusters for CoMTb was twice that for
the control bead (p , 0.005), and inhibition of MT1-MMP activity
resulted in a 44% reduction in the diameter of the monocyte clusters
(Fig. 7E, p, 0.005), whereas the matched isotype control Ab had no
effect on monocyte migration toward CoMTb. Therefore, MT1-MMP
is required for monocyte migration in this cellular model of TB.
Discussion
We demonstrated in TB patients and in a human cell culture model
thatMT1-MMP expression in TB regulates both collagen destruction
and cellular migration. MT1-MMP mRNA levels are increased in
sputum of patients with active pulmonary TB, and MT1-MMP is
expressed within granulomas of TB patients. M. tuberculosis in-
fection and monocyte-dependent networks upregulate primary hu-
man monocyte expression of MT1-MMP and cause degradation of
type I collagen, the main structural protein of the lung. Additionally,
monocyte migration in TB is dependent on MT1-MMP, as shown
by a novel agarose bead assay. MT1-MMP may play a pivotal role
in the immunopathology of human TB by both degrading collagen
and regulating cellular migration.
MT1-MMP has previously been implicated in TB pathogenesis
by unbiased approaches. Gene expression profiling demonstrates
that MT1-MMP is upregulated in M. tuberculosis–infected human
FIGURE 4. MT1-MMP is expressed in TB granulomas from patients
and is driven by monocyte–monocyte networks. (A) Lung biopsies from
five patients with culture-proven M. tuberculosis infection and control
tissue from uninvolved lung parenchyma of patients with lung cancer were
immunostained for MT1-MMP. In control biopsies, MT1-MMP immuno-
staining is present only in alveolar macrophages (i and ii). In TB, MT1-
MMP immunoreactivity is present throughout the granuloma, expressed by
both giant cells and epithelioid macrophages (iii and iv). White arrows
indicate Langerhans multinucleate giant cells, surrounded by epithelioid
macrophages. (B) Monocytes were stimulated with CoMTb to model in-
tercellular networks. MT1-MMP expression was measured in unpermea-
balized and permeabalized monocytes by immunofluorescent staining and
microscopy. Blue is DAPI nuclear stain, magenta is MT1-MMP. CoMTb
stimulation increased both surface and intracellular MT1-MMP expression
at 24 h. Images are representative of three independent experiments.
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macrophages (31), and a microarray study of human lung TB
granulomas excised at surgery showed MT1-MMP gene expres-
sion to be 28.6-fold greater than in normal lung (19). Similarly,
whole-blood gene expression profiling shows that MT1-MMP
expression is higher in patients with active TB than in healthy
controls (32) and MT1-MMP gene expression is elevated in
nonhuman primate lungs 4 wk after TB infection (18). However,
the functional significance of MT1-MMP activity has not previ-
ously been investigated. Multiple MMPs are emerging as impor-
tant mediators in TB (11, 17, 20), and different MMPs may
regulate specific aspects of immunopathology (33). The role of
individual MMPs in TB pathology is likely to be both time- and
cell-dependent. For example, MMP-9 derived from epithelial cells
regulates cellular recruitment to the granuloma by inducing mi-
gratory gradients (11) whereas macrophage-derived MMP-1 is one
effector of collagen destruction (17). MT1-MMP neutralization
inhibited collagen destruction, suggesting that MT1-MMP is ei-
ther the dominant collagenase in the immediate pericellular en-
vironment early in infection, consistent with other reports (12, 16,
34), or alternatively it is activating the proform of MMP-1 se-
creted by monocytes by enzymatic cleavage (27). MT1-MMP may
regulate both cell migration and collagen destruction, and these
processes may be co-dependent because collagen cleavage may be
necessary for cells to migrate through the extracellular matrix.
We demonstrated that MT1-MMP colocalized with collagen
destruction and that MT1-MMP neutralization could abrogate this
FIGURE 5. M. tuberculosis–driven monocyte networks upregulate MT1-MMP expression, regulated by p38 MAPK and GPCR signaling. (A) Human
monocytes were stimulated with CoMTb, and MT1-MMP expression was analyzed at 24 h by flow cytometry. CoMTb upregulated MT1-MMP surface
expression. (B) Analysis of fluorescence from three donors confirms increased monocyte surface MT1-MMP. (C) CoMTb causes a progressive increase in
MT1-MMP mRNA relative to unstimulated monocytes. (D) Monocytes were stimulated with CoMTb and TIMP secretion was analyzed at 24 h. CoMTb
increased TIMP-1 secretion. (E) Monocyte secretion of the specific MMP-14 inhibitor TIMP-2 is suppressed in CoMTb. (F) CoMTb stimulation increased
p38 and ERK MAPK phosphorylation in monocytes at 30 min compared with unstimulated monocytes. Total p38 and ERK were unchanged. (G and H)
Monocytes were preincubated with the p38 MAPK inhibitor SB203580 (SB) or pertussis toxin (PT) for 1 h prior to stimulation with CoMTb. MT1-MMP
surface expression was measured by flow cytometry. Inhibition of p38 MAPK pathway (E) and GPCR signaling (F) downregulated CoMTb driven MT1-
MMP expression at 24 h. The mean values6 SD are shown of experiments performed in triplicate on at least two occasions.*p, 0.05, **p, 0.01, ***p,
0.001 by Student t test.
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proteolysis, implying a role in matrix destruction. Consistent with
this, MT1-MMP causes matrix breakdown in other destructive
pulmonary pathologies. MT1-MMP expression is upregulated in
alveolar macrophages of smokers (35), and IL-13–driven em-
physema in transgenic mouse models is associated with MT1-
MMP upregulation (36). MT1-MMP is expressed in asthma and
bronchiectasis, diseases that are characterized by pulmonary
matrix remodeling (37). Other infectious conditions can upreg-
FIGURE 6. M. tuberculosis–induced intercel-
lular networks stimulate monocyte migration.
Agarose beads impregnated with RPMI 1640
(control) or CoMTb were set on slides coated
with type I collagen. Monocytes were seeded
on these slides. White arrows indicate the di-
rection toward the bead center and dashed lines
indicate the edge of the bead. MT1-MMP ex-
pression was measured in monocytes by immu-
nofluorescent staining and microscopy. Magenta
is MT1-MMP. (A and D) Light microscopy
images show monocytes migrate toward the
CoMTb bead at 24 h, forming clusters not
observed for the control bead. (B and E) Surface
MT1-MMP expression on monocytes migrating
toward the CoMTb bead is greater than for the
monocytes around the control bead. (C and F)
Merged confocal and fluorescence images. Images
shown are representative of three independent
experiments.
FIGURE 7. MT1-MMP is necessary for
M. tuberculosis–driven monocyte migration.
(A and B) Light microscopy images show mi-
grating monocytes forming clusters around the
CoMTb drop at 24 h. (C) Neutralization of
MT1-MMP activity with an inhibitory anti–
MT1-MMP Ab reduces monocyte migration.
(D) An isotype control Ab did not affect cellular
migration. (E) The maximum diameter of the
monocyte clusters were analyzed, with images
taken at four radial points per bead. Quantifica-
tion confirms reduced monocyte migration with
MT1-MMP neutralization. Data are means6 SD
from a single experiment and are representative
of two independent experiments. ***p , 0.001
by one-way ANOVAwith a Tukey post hoc test.
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ulate MT1-MMP. For example, in hepatitis B–induced hepato-
cellular carcinoma, intrahepatic metastasis is driven by hepatitis
B virus protein upregulating MT1-MMP (38). However, the role
of MT1-MMP in bacterial infection has not been extensively
studied.
We found that MT1-MMP was widely expressed in human TB
granulomas, whereas bacilli are very sparse (26), leading us to
investigate intercellular networks. Monocyte–monocyte signal-
ing upregulated MT1-MMP expression and this was dependent
on p38 MAPK and GPCR signaling. Although TIMP-1 was
upregulated by M. tuberculosis infection, this does not inhibit
MT1-MMP activity (27), whereas the specific inhibitor TIMP-2
was suppressed by monocyte intercellular networks, further
skewing the local environment to matrix destruction. Consistent
with our findings, p38 MAPK regulates MT1-MMP expression
in fibronectin-stimulated macrophages (39). Studies in malignant
cells have identified a role for ERK in driving constitutive MT1-
MMP expression (40, 41), but we did not demonstrate ERK
regulation of MT1-MMP in primary monocytes, indicating
stimulus- and cell-specific regulation. We demonstrated that secre-
tion of multiple chemokines is upregulated in M. tuberculosis–
infected monocytes. Chemokines are critical to leukocyte migration
to TB granulomas (42), but no single chemokine appears to be
dominant due to redundancy within the signaling system. To
perform global chemokine inhibition, we studied the effect of
pertussis toxin, which inhibits GPCR signaling, and demon-
strated that this suppressed CoMTb-driven MT1-MMP upregu-
lation, suggesting a role for cytokines in upregulating MT1-
MMP. Consistent with this, CCL2 stimulation of monocytes
transmigrating through endothelium causes MT1-MMP cluster-
ing at motility-associated protrusions (43), and CCL2 and
CXCL8 promote MT1-MMP surface expression, clustering, and
activity in endothelial cells (30). However, in our system, CCL2
as a single stimulus did not upregulate total surface expression of
MT1-MMP, suggesting that multiple factors may synergize to
drive MT1-MMP. These may include either multiple host cyto-
kines (44) or both host- and pathogen-secreted mediators as
described for MMP-9 (11, 45).
Although the granuloma has traditionally been viewed as a host
strategy to control mycobacterial growth, accumulating evidence
suggests that monocyte migration may have deleterious effects to
the host. In the Mycobacterium marinum zebrafish model, mac-
rophages migrating into granulomas permit bacterial expansion
and can disseminate infection (46). In mice, intranasal adminis-
tration of poly(I:C), a type I IFN inducer, caused a CCR2-
dependent excessive accumulation of monocytes in the lungs of
M. tuberculosis–infected mice, leading to increased bacterial
burden and decreased survival (47). However, whereas the che-
motactic gradients driving the cellular recruitment have been
dissected, the proteases driving leukocyte migration have not been
identified (48). We demonstrate utilizing the agarose drop assay
that MT1-MMP surface expression is driven by M. tuberculosis–
induced intercellular networks and monocyte migration is MT1-
MMP–dependent. Modulating MT1-MMP activity in TB may
have diverse effects, for example by affecting intracellular sig-
naling pathways regulated by MT1-MMP such as ERK and PI3K
(49, 50). Therefore, investigating the global effect of MT1-MMP
inhibition will require careful analysis in appropriate animal
model systems.
MT1-MMP is critical to cellular migration in other pathologies
(14, 16, 51), and in the agarose bead assay, inhibition suppressed
cell migration, suggesting that it is the key collagenase in this
process. MT1-MMP may be driving leukocyte migration by
multiple mechanisms. First, MT1-MMP cleavages extracellular
matrix at the leading edge of the cell, and also modification of cell
surface proteins to promote the organized cell adhesion–de-adhesion
required for migration (52, 53). Second, MT1-MMP–dependent
cleavage of other cell surface proteins that interact with ECM
components, such as CD44, integrins, and transglutaminase, are
also considered important to migration of malignant cells (54–56).
For example, MT1-MMP cleaves CD44 to produce a soluble
fragment. Expression of MT1-MMP or CD44 in a breast cancer
cell line alone did not stimulate cell migration, but coexpression
did. Coexpression of a CD44 deletion mutant, which cannot be
cleaved by MT1-MMP, resulted in loss of cell migration (56).
Third, it has been postulated that MT1-MMP promotes cell mi-
gration by driving ERK MAPK phosphorylation. In a human fi-
brosarcoma cell line, TIMP-2 binding to MT1-MMP drove ERK
signaling, which increased cell migration independently of the
direct enzymatic activity of MT1-MMP (57).
In summary, we have demonstrated that MT1-MMP expression
is increased in pulmonary TB and is functionally active, contrib-
uting to local tissue destruction and leukocyte recruitment to the
granuloma. Therefore, MT1-MMP may represent a previously
unrecognized regulator of these central immunopathological pro-
cesses in human TB. Host-targeted therapies are emerging as
a novel therapeutic paradigm in TB (58, 59), and the potential
effect of such interventions on MMP-dependent cell migration and
matrix destruction deserves evaluation.
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